Our History

BRIM Founded

2014

Series A (USD 4M)

BRM132 In-licensed

2015

Series B (USD 26M)

PDSP Platform In-licensed

2016

BRM421 U.S. IND Approval

2017

BRM421 U.S. FIH Study

BRM132 U.S. IND Approval

2018

Series C (USD 6M)

2019

BRM421 U.S. SIH Study Completed

BRM521 Pre-clinical Studies On-going

2020

BRM421 CN Right Licensed to CGP

Subsidiary Ascendo Biotech Formed (raised USD 12M)